

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
29 September 2022 (29.09.2022)



(10) International Publication Number  
**WO 2022/200810 A1**

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 35/00 (2006.01)  
A61K 31/713 (2006.01)

(21) International Application Number:

PCT/GB2022/050757

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,390 26 March 2021 (26.03.2021) US  
63/318,927 11 March 2022 (11.03.2022) US

(71) Applicant: MINA THERAPEUTICS LIMITED

[GB/GB]; Translation & Innovation Hub, 84 Wood Lane,  
London W12 0BZ (GB).

(72) Inventors: TAN, Choon Ping; MiNA Therapeutics Lim-

ited, Translation & Innovation Hub, 84 Wood Lane, Lon-  
don W12 0BZ (GB). SINIGAGLIA, Laura; MiNA Ther-  
apeutics Limited, Translation & Innovation Hub, 84 Wood  
Lane, London W12 0BZ (GB). GOMEZ, Valenti; MiNA  
Therapeutics Limited, Translation & Innovation Hub, 84  
Wood Lane, London W12 0BZ (GB). RYAN, Brid; Mi-  
NA Therapeutics Limited, Translation & Innovation Hub,  
84 Wood Lane, London W12 0BZ (GB). SÆTROM, Pål;  
Østtunveien 5, NO 7023 Trondheim (NO). HEGRE, Siv  
Anita; Frydenbergvegen 3C, NO 7050 Trondheim (NO).  
DEBACKER, Alexandre; MiNA Therapeutics Limited,  
Translation & Innovation Hub, 84 Wood Lane, London  
W12 0BZ (GB).

(74) Agent: CHAPMAN, Desmond Mark et al.; Carpmals  
& Ransford LLP, One Southampton Row, London WC1B  
5HA (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every


kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TMEM173 SARNA COMPOSITIONS AND METHODS OF USE

FIG. 2



(57) Abstract: The disclosure relates to a saRNAs useful in upregulating the expression of a target gene and therapeutic compositions comprising the saRNA, wherein the target gene is TMEM173. Methods of using the saRNA and the therapeutic compositions are also provided.

WO 2022/200810 A1